These discoveries and the mechanistic intersection of ALS with SMA, suggest that gene therapy strategies able to augment SMN levels may be beneficial to both fALS and sALS patients, perhaps not in isolation, but as part of a combinatorial approach. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.